Suven bags 4 patents in Australia, Eurasia, Israel, US

The Dollar Business Bureau

Suven Life Sciences has received patents for its New Chemical Entities (NCEs) in Australia, Eurasia, Israel and USA. The new drug is used in the treatment of cognitive impairment related with neurodegenerative disorders. The patents are valid till 2032, 2030 and 2031 respectively, the company said in a statement on Monday.

With these, Suven has around twenty-four granted patents from Australia, seventeen patents from Eurasia, nine from Israel and another twenty-four from USA. These granted patents are intellectual property of the company. They are accomplished through the firm’s internal efforts of the research and development team, it said.

The granted patents include the class of selective H3 ligands from Suven which are being developed as therapeutic agents for neurodegenerative disorders. The newly invented products are likely to be out-licensed at different phases of clinical research and development such as Phase-I or Phase-II.

The granted patents have encouraged the company in developing more drugs in the treatment of central nervous system (CNS) arena. The new molecules that are being developed by the company are highly useful for treating cognitive disorders.  The potential for these drugs in the pipeline is very huge in the international market, said Venkat Jasti, CEO of Suven.

The biopharmaceutical company is focused in researching and developing new drugs that are best in class for CNS therapies. The company has three clinical stage compounds, a phase-I undergoing candidate SUVN-D4010 meant to be used for Alzheimer’s disease and Schizophrenia.

Other than these, the company currently has ten internally discovered therapeutic drugs in pre-clinical stage that are meant to be used in treating diseases such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.